Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SNTS
- CUSIP: 80281730
- Web: N/A
Average Prices:- 50 Day Moving Avg: $24,383.00
- 200 Day Moving Avg: $23,275.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 19.85
- P/E Growth: 0
Dividend:
Frequently Asked Questions for Santarus (NASDAQ:SNTS)
What is Santarus' stock symbol?
Santarus trades on the NASDAQ under the ticker symbol "SNTS."
Who are some of Santarus' key competitors?
Some companies that are related to Santarus include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), ResMed (RMD), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI) and Opko Health (OPK).
How do I buy Santarus stock?
Shares of Santarus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Santarus' stock price today?
One share of Santarus stock can currently be purchased for approximately $31.96.
MarketBeat Community Rating for Santarus (NASDAQ SNTS)MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Santarus (NASDAQ:SNTS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Santarus (NASDAQ:SNTS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Santarus (NASDAQ:SNTS)Earnings History by Quarter for Santarus (NASDAQ SNTS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2013 | Q313 | $0.33 | $0.45 | $94.45 million | $98.79 million | View | N/A |  |
| 8/6/2013 | Q2 2013 | $0.18 | $0.94 | $82.90 million | $89.40 million | View | N/A | |
| 5/6/2013 | Q1 2013 | $0.15 | $0.25 | $74.70 million | $79.44 million | View | N/A | |
| 3/4/2013 | Q4 2012 | $0.01 | $0.08 | $62.02 million | $70.20 million | View | N/A | |
| 11/7/2012 | Q312 | $0.10 | $0.13 | $53.04 million | $54.70 million | View | N/A | |
| 8/7/2012 | | $0.08 | $0.05 | | | View | N/A | |
| 5/8/2012 | | ($0.01) | $0.01 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Santarus (NASDAQ:SNTS)Current Year EPS Consensus Estimate: $1.37 EPS
Next Year EPS Consensus Estimate: $1.61 EPS
Dividend History for Santarus (NASDAQ:SNTS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Santarus (NASDAQ:SNTS)Insider Trades by Quarter for Santarus (NASDAQ:SNTS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/16/2013 | Gerald Proehl | CEO | Sell | 56,643 | $31.95 | $1,809,743.85 | |
| 12/16/2013 | Kent Snyder | Director | Sell | 7,500 | $31.95 | $239,625.00 | |
| 12/9/2013 | Meules Julie De | VP | Sell | 15,165 | $31.95 | $484,521.75 | |
| 11/15/2013 | Kent Snyder | Director | Sell | 7,500 | $32.01 | $240,075.00 | |
| 11/11/2013 | Meules Julie De | VP | Sell | 15,165 | $31.94 | $484,370.10 | |
| 10/15/2013 | Gerald Proehl | CEO | Sell | 50,000 | $22.32 | $1,116,000.00 | |
| 10/15/2013 | Kent Snyder | Director | Sell | 7,500 | $22.31 | $167,325.00 | |
| 10/10/2013 | Debra Crawford | CFO | Sell | 16,614 | $21.90 | $363,846.60 | |
| 10/9/2013 | Meules Julie De | VP | Sell | 15,165 | $21.14 | $320,588.10 | |
| 10/8/2013 | Maria Bedoya-Toro | SVP | Sell | 10,000 | $21.39 | $213,900.00 | |
| 10/7/2013 | Carey Fox | SVP | Sell | 17,100 | $21.91 | $374,661.00 | |
| 10/1/2013 | William C Denby | VP | Sell | 24,450 | $23.03 | $563,083.50 | |
| 9/16/2013 | Gerald Proehl | CEO | Sell | 50,000 | $22.19 | $1,109,500.00 | |
| 9/16/2013 | Kent Snyder | Director | Sell | 7,500 | $22.18 | $166,350.00 | |
| 9/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $22.38 | $425,220.00 | |
| 9/9/2013 | Carey J Fox | SVP | Sell | 17,100 | $22.19 | $379,449.00 | |
| 9/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $21.90 | $332,113.50 | |
| 9/5/2013 | Michael D Step | SVP | Sell | 30,303 | $23.17 | $702,120.51 | |
| 9/3/2013 | William Denby | VP | Sell | 24,450 | $22.43 | $548,413.50 | |
| 8/15/2013 | Kent Snyder | Director | Sell | 7,500 | $25.89 | $194,175.00 | |
| 8/12/2013 | Debra Crawford | CFO | Sell | 19,000 | $26.40 | $501,600.00 | |
| 8/9/2013 | Meules Julie De | VP | Sell | 15,165 | $26.55 | $402,630.75 | |
| 8/8/2013 | Maria Bedoya-Toro | SVP | Sell | 10,000 | $27.35 | $273,500.00 | |
| 8/7/2013 | Carey Fox | SVP | Sell | 17,100 | $27.36 | $467,856.00 | |
| 8/2/2013 | E David Ballard II | SVP | Sell | 9,000 | $24.96 | $224,640.00 | |
| 8/1/2013 | William C Denby | VP | Sell | 24,450 | $24.77 | $605,626.50 | |
| 7/15/2013 | Kent Snyder | Director | Sell | 35,000 | $25.36 | $887,600.00 | |
| 7/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $23.17 | $440,230.00 | |
| 7/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $23.52 | $356,680.80 | |
| 7/8/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $23.34 | $233,400.00 | |
| 7/5/2013 | Michael D Step | SVP | Sell | 30,301 | $21.76 | $659,349.76 | |
| 7/3/2013 | Warren E Hall | VP | Sell | 28,749 | $21.54 | $619,253.46 | |
| 7/2/2013 | E David Ballard II | SVP | Sell | 9,000 | $21.45 | $193,050.00 | |
| 7/1/2013 | William C Denby | VP | Sell | 25,050 | $21.56 | $540,078.00 | |
| 6/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $21.45 | $407,550.00 | |
| 6/10/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $21.57 | $215,700.00 | |
| 6/10/2013 | Meules Julie A De | VP | Sell | 15,165 | $21.67 | $328,625.55 | |
| 6/7/2013 | Carey J Fox | SVP | Sell | 17,100 | $20.54 | $351,234.00 | |
| 6/3/2013 | Daniel D Burgess | Director | Sell | 8,000 | $21.34 | $170,720.00 | |
| 6/3/2013 | E David Ballard II | SVP | Sell | 9,000 | $21.34 | $192,060.00 | |
| 6/3/2013 | William C Denby | VP | Sell | 24,450 | $21.46 | $524,697.00 | |
| 5/15/2013 | Cha Alessandro Della | Director | Sell | 16,500 | $21.33 | $351,945.00 | |
| 5/15/2013 | Technologies Ltd Cosmo | Major Shareholder | Sell | 4,887,500 | $17.68 | $86,411,000.00 | |
| 5/14/2013 | Michael E Herman | Director | Sell | 25,000 | $20.77 | $519,250.00 | |
| 5/10/2013 | Debra P Crawford | CFO | Sell | 18,643 | $19.27 | $359,250.61 | |
| 5/9/2013 | Meules Julie A De | VP | Sell | 15,165 | $20.10 | $304,816.50 | |
| 5/8/2013 | Maria E Bedoya-Toro | SVP | Sell | 10,000 | $20.53 | $205,300.00 | |
| 5/1/2013 | Daniel D Burgess | Director | Sell | 8,000 | $17.88 | $143,040.00 | |
| 5/1/2013 | William C Denby | VP | Sell | 24,450 | $17.90 | $437,655.00 | |
| 4/10/2013 | Debra P Crawford | CFO | Sell | 19,000 | $16.82 | $319,580.00 | |
| 12/18/2012 | Ted W Love | Director | Buy | 185,000 | $10.88 | $2,012,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Santarus (NASDAQ:SNTS)
Latest Headlines for Santarus (NASDAQ:SNTS)
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Santarus (SNTS) Chart for Thursday, July, 20, 2017
